

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Bayzed Health Group Inc
佰澤醫療集團

(Incorporated in Cayman Islands with limited liability)
(Stock Code: 2609)

**VOLUNTARY ANNOUNCEMENT
STRATEGIC COOPERATION WITH
WEILIAN WEITONG AND MINGYUE MEDICAL**

This announcement is made by Bayzed Health Group Inc (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on May 20, 2026, Bayzed Medical Investment Group Company Limited* (佰澤醫療投資集團有限公司), a wholly owned subsidiary of the Company entered into strategic cooperation agreements (the “**Strategic Cooperation Agreements**”) with each Shanghai Weichuang Weilian Weitong Health Management Co., Ltd. (上海微創微聯微通健康管理有限公司)(“**Weilian Weitong**”) and Shanghai Mingyue Medical Technology Co., Ltd. (上海明悅醫療科技有限公司) (“**Mingyue Medical**”). Weilian Weitong and Mingyue Medical are both subsidiaries of MicroPort Scientific Corporation (Stock Code: 00853.HK) (together with its subsidiaries, the “**MicroPort Scientific Group**”).

Pursuant to the Strategic Cooperation Agreements, the parties will carry out comprehensive cooperation in the healthcare sector to jointly enhance the standard of medical services. The key terms include:

- (i) **Supply chain cooperation:** Weilian Weitong and Mingyue Medical will provide the hospitals under the Group with a full range of high-value consumables and comprehensive solutions across all business segments of the MicroPort Scientific Group.
- (ii) **Development of cardiovascular and cerebrovascular disciplines:** The parties will jointly establish regional cardiovascular and cerebrovascular diagnosis and treatment centers at the hospitals under the Group, and will cooperate in respect of equipment and technologies, specialist resources, and site facilities.
- (iii) **Establishment of surgical robotics diagnosis and treatment centers:** The parties will jointly establish endoscopic and orthopedic surgical robot centers at the hospitals under the Group, creating a specialized intelligent platform integrating clinical diagnosis and treatment, technical training, scientific research, and academic exchange.

The Board believes that these strategic cooperations fully leverage the complementary strengths of all parties. Weilian Weitong and Mingyue Medical both focus on medical artificial intelligence and information technology. Their advanced medical equipment, innovative technologies, and research and development capabilities will not only help to enhance the core “diagnosis” and “treatment” capabilities of hospitals under the Group in complex diseases and minimally invasive surgery, together with their integrated solutions in areas such as endocrinology and rehabilitation, but will also help the Group further establish a closed-loop pathway linking high-quality in-hospital treatment with continuous out-of-hospital rehabilitation. This will provide solid clinical and technical support for the Group’s comprehensive implementation of the “eight-ring” service framework of “prevention, screening, diagnosis, treatment, rehabilitation, management, connectivity and companionship,” and will also provide a high-quality hardware foundation and delivery capability for the Group to expand its service coverage through regional diagnosis and treatment centers and to strengthen its “H@H” (Hospital at Home) continuous healthcare service model. As such, the Board believes that the cooperation is in the interests of the Company and its shareholders as a whole and will be conducive to expanding the Group’s service coverage, enhancing brand influence, and promoting broader access to quality medical resources.

The Board also believes that this cooperation will also bring multiple benefits to Weilian Weitong and Mingyue Medical, including: leveraging the Group’s extensive regional hospital network to broaden application scenarios for their high-value consumables and integrated solutions in cardiovascular, cerebrovascular, orthopedics, endocrinology, rehabilitation and other fields, thereby accelerating the commercialization of innovative products; jointly establishing regional cardiovascular and cerebrovascular diagnosis and treatment centers and surgical robot centers to create benchmark demonstration sites integrating clinical diagnosis and treatment, technical training, and academic exchange for cutting-edge equipment such as endoscopic and orthopedic surgical robots, thereby strengthening their brand influence in the field of precision medicine; utilizing abundant clinical feedback accumulated through the Group’s implementation of the “H@H” strategy and “eight-ring” service framework to establish a close “medicine-engineering integration” mechanism, supporting the continued research and development and iteration of their medical AI and innovative technologies; and promoting the extension of their service model from pure product delivery to becoming a deep cooperation partner encompassing clinical training, research support, and integrated solutions.

To the best of the knowledge, information and belief of the Directors, having made all reasonable enquiries, Weilian Weitong, Mingyue Medical and their ultimate beneficial owners are third parties independent of and not connected with the Company and its connected persons as defined under the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The entering into of the Strategic Cooperation Agreements do not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules and shall not be subject to reporting, announcement and independent shareholders’ approval requirements under the Listing Rules.

The Board wishes to emphasise that the implementation of the strategic cooperations lay the foundation for a long-term strategic partnerships between the parties thereto, such cooperation will be subject to the execution of appropriate definitive agreement(s).

The Board wishes to further emphasise that as at the date of this announcement, no definitive agreement in relation to any specific project under the strategic cooperations have been entered into by the parties or the Company. As such, the strategic cooperations may or may not be materialised. In the event that any specific project under the strategic cooperations materialise, the Company will comply with the relevant requirements under the Listing Rules and make further disclosure in accordance with all the applicable requirements as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Bayzed Health Group Inc
(佰澤醫療集團)
Dr. Chen Haoyang
Chairman and Executive Director

Hong Kong, May 20, 2026

As at the date of this announcement, the Board comprises executive Directors of Dr. Chen Haoyang, Mr. Zhao Yongkai, Ms. Xu Xu, Mr. Lu Jizhong and Mr. Feng Yu; and independent non-executive Directors of Mr. Chan Hok Leung, Ms. Liu Shuang and Dr. Guo Wei.